Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:1.10.3.1 (
tyrosinase
)
9,065
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The objective of this study was to compare the charge effect of
methyl myristate
loaded in neutral (Brij 72/cholesterol at 7:3), cationic (Brij 72/cholesterol/dimethyl dioctadecyl ammonium bromide at 7:3:0.65) and anionic niosomes (Brij 72/cholesterol/dicetyl phosphate at 7:3:0.65) for physicochemical characteristics, cytotoxicity in fibroblasts and B16F10 melanoma cells as well as melanogenesis induction activity. The maximum loading and percentage entrapment of
methyl myristate
were 4.5, 90.68 +/- 7.95 in neutral; 11.0, 92.54 +/- 6.32 in cationic and 0.1% w/w, 74.43 +/- 1.86% in anionic niosomes, respectively. All
methyl myristate
loaded niosomes were in unilamellar structure under transmission electron microscope and in nanosize at initial and after 3-month storage. The percentages of
methyl myristate
remaining in all niosomes kept at 4 +/- 2, 30 +/- 2 and 45 +/- 2 degrees C for 3 months were about 82, 74 and 72%, respectively, while the dry free
methyl myristate
indicated 97.82 +/- 1.74, 96.56 +/- 2.91 and 91.39 +/- 4.32%, respectively. Blank neutral, blank cationic and
methyl myristate
loaded neutral and cationic niosomes exhibited moderate cytotoxicity in fibroblasts and B16F10 melanoma cells at 56.64 +/- 3.19, 59.72 +/- 1.51; 73.81 +/- 2.86, 82.51 +/- 0.20; 47.34 +/- 2.13, 52.67 +/-2.78 and 73.20 +/- 3.49, 84.34 +/- 2.75% cell viability, respectively. Blank anionic and
methyl myristate
loaded anionic niosomes indicated no cytotoxicity in both cells. Cytotoxic ratio of cell viability in normal and cancer cells of all niosomes indicated no toxic effect to normal cells.
Methyl myristate
loaded cationic niosomes demonstrated the highest melanin induction with
tyrosinase
activity of 1.42 and 1.70 folds of the control and 1.14 and 1.59 folds higher than theophylline, respectively. This study has suggested the potential of
methyl myristate
loaded cationic niosomes for canities treatment.
...
PMID:Melanogenesis of methyl myristate loaded niosomes in B16F10 melanoma cells. 2362 Oct 22